CC
Casdin Capital Portfolio holdings
AUM
$1.1B
This Quarter Return
-19.64%
1 Year Return
+24.98%
3 Year Return
+152.8%
5 Year Return
+110.01%
10 Year Return
–
AUM
$966M
AUM Growth
+$966M
(-9.6%)
Cap. Flow
+$97.8M
Cap. Flow
% of AUM
10.12%
Top 10 Holdings %
Top 10 Hldgs %
64.34%
Holding
33
New
2
Increased
11
Reduced
6
Closed
–
Top Buys
| 1 |
Sarepta Therapeutics
SRPT
|
$41M |
| 2 |
BLUE
bluebird bio
BLUE
|
$22M |
| 3 |
CareDx
CDNA
|
$18.1M |
| 4 |
Agios Pharmaceuticals
AGIO
|
$14.3M |
| 5 |
Fulcrum Therapeutics
FULC
|
$5.61M |
Top Sells
| 1 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
$8.87M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$4.02M |
| 3 |
BOLD
Audentes Therapeutics, Inc
BOLD
|
$2.95M |
| 4 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
$2.09M |
| 5 |
Editas Medicine
EDIT
|
$1.48M |
Sector Composition
| 1 | Healthcare | 81.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ONCE
1
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $83.7M | 8.66% | 863,300 -21,500 | -2% | -$2.09M |
|
|
NVTA
2
DELISTED
Invitae Corporation
NVTA
| $74M | 7.65% | 3,838,388 | – | – |
|
3
Codexis
CDXS
$246M
| $69.6M | 7.2% | 5,073,780 | – | – |
|
|
BPMC
4
DELISTED
Blueprint Medicines
BPMC
| $69.1M | 7.15% | 940,000 | – | – |
|
|
5
Sarepta Therapeutics
SRPT
$1.78B
| $66.3M | 6.86% | 880,000 +545,000 | +163% | +$41M |
|
|
MYOK
6
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $58.1M | 6.02% | 1,115,000 -170,000 | -13% | -$8.87M |
|
|
BLUE
7
DELISTED
bluebird bio
BLUE
| $56.2M | 5.82% | 612,500 +240,000 | +64% | +$22M |
|
|
SAGE
8
DELISTED
Sage Therapeutics
SAGE
| $56.1M | 5.81% | 400,000 | – | – |
|
|
9
Alnylam Pharmaceuticals
ALNY
$58.5B
| $48.3M | 4.99% | 600,000 -50,000 | -8% | -$4.02M |
|
10
BioLife Solutions
BLFS
$1.2B
| $40.4M | 4.18% | 2,428,571 | – | – |
|
11
Fate Therapeutics
FATE
$120M
| $39.6M | 4.1% | 2,550,000 | – | – |
|
12
Dianthus Therapeutics
DNTH
$759M
| $31.3M | 3.24% | 3,048,121 +45,000 | +1% | +$462K |
|
|
13
Agios Pharmaceuticals
AGIO
$2.19B
| $30.3M | 3.14% | 935,000 +440,000 | +89% | +$14.3M |
|
|
BOLD
14
DELISTED
Audentes Therapeutics, Inc
BOLD
| $24.2M | 2.5% | 860,000 -105,000 | -11% | -$2.95M |
|
|
15
CareDx
CDNA
$727M
| $22.6M | 2.34% | 1,000,000 +800,000 | +400% | +$18.1M |
|
|
GNMK
16
DELISTED
GenMark Diagnostics, Inc
GNMK
| $20.4M | 2.11% | 3,365,000 | – | – |
|
17
Voyager Therapeutics
VYGR
$186M
| $19.4M | 2.01% | 1,128,075 | – | – |
|
18
Illumina
ILMN
$15.8B
| $18.3M | 1.89% | 60,000 | – | – |
|
|
GRTS
19
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $15.3M | 1.58% | 1,770,000 | – | – |
|
20
Q32 Bio
QTTB
$20.9M
| $14.8M | 1.54% | 820,000 +75,000 | +10% | +$1.36M |
|
|
GBT
21
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $14.6M | 1.51% | 300,000 | – | – |
|
22
Adaptive Biotechnologies
ADPT
$2.01B
| $14.3M | 1.48% | 463,125 | – | – |
|
23
Sangamo Therapeutics
SGMO
$157M
| $13.2M | 1.36% | 1,455,000 -75,000 | -5% | -$679K |
|
24
Alector
ALEC
$238M
| $11.7M | 1.21% | 811,039 +260,000 | +47% | +$3.75M |
|
25
Denali Therapeutics
DNLI
$2.23B
| $9.96M | 1.03% | 650,000 +250,000 | +63% | +$3.83M |
|